StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.64+0.16 (+2.47%)

Close on Nov 18, 2026Market cap $113.58MP/E –Yield –

Atrium Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Atrium Therapeutics

Atrium Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Atrium Therapeutics figures

See a number that looks wrong?